alexa Antiplatelet Agents in Diabetic Patients: Clinical Adva
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Antiplatelet Agents in Diabetic Patients: Clinical Advances and Remaining Questions

Pierre Sabouret1*, Magali Taiel-Sartral2, Jean-Philippe Kevorkian3 and Bruno Vergès4
1Institute of Cardiology, INSERM UMRS937, Pitié-Salpêtrière Hospital (AP-HP), University Paris, France
2Cardiovascular Intensive Care Unit, Lilly France-24 boulevard Vital Bouhot CS, Neuilly-sur-Seine, France
3Department of Diabetology, Lariboisière Hospital, 2 rue Ambroise Paré, Paris, France
4Endocrinology, Diabetes and Metabolic Diseases Service, 14 rue Gaffarel, BP, Dijon, France
Corresponding Author : Pierre Sabouret
Cardiology Department, Heart Institute
Pitié-Salpêtrière University Hospital
47-83 bld de l'Hôpital, 75013 Paris, France
Tel: +33181793507
E-mail: [email protected]
Received June 08, 2014; Accepted July 31, 2014; Published August 10, 2014
Citation: Sabouret P, Sartral MT, Kevorkian JP, Verges B (2014) Antiplatelet Agents in Diabetic Patients: Clinical Advances and Remaining Questions. J Clin Exp Cardiolog 5:330. doi:10.4172/2155-9880.1000330
Copyright: © 2014 Sabouret P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Patients with diabetes mellitus (DM) are at significantly greater risk for major cardiovascular events (MACE) than non-DM patients. Primary and secondary prevention of cardiovascular disease (CVD) involves a multifactorial approach that aims to treat the cluster of risk factors associated with this condition including blood disorders and clinical features, such as hyperglycaemia, dyslipidemia, hypercoagulation, obesity and hypertension. Platelet activation and aggregability play a key role in the genesis of arterial thrombus secondary to plaque rupture. For patients in secondary prevention, inhibition of platelet function is crucial to significantly decrease the rate of MACE. Inhibiting plaque rupture would therefore prevent platelet aggregation. For patients with DM presenting with an acute coronary syndrome (ACS), a dual antiplatelet therapy with antagonism of COX1 and P2Y12 is central to their treatment, especially in the setting of percutaneous coronary intervention (PCI) and stenting. Large randomized trials have demonstrated that platelet inhibition with the P2Y12 antagonist clopidogrel, is associated with a better short and long-term prognosis after an acute coronary syndrome. Despite the clinical benefits of clopidogrel in patients with ACS, it has limitations in urgent and early PCI due to its slow onset of action, large interindividual variability and drug-drug interactions resulting in inconsistent drug response with reduced efficacy, especially in patients with diabetes. Therefore, newer drugs with a rapid onset of action, and a more potent and predictable effect have been developed. Prasugrel and ticagrelor have demonstrated net clinical benefit over clopidogrel in two major randomized trials, including a large number of diabetic patients, in patients presenting with non-ST elevation ACS (NSTE-ACS) and ST-elevation ACS (STE-ACS) revascularized by PCI. The aim of this review is to provide an overview of aspirin, P2Y12 receptor antagonists, and Glycoprotein (GP) IIb-IIIa inhibitors in the management of diabetic patients, with a focus on perspectives in optimal and appropriate agent selection and timing of treatment in both primary and secondary prevention.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version